Latest: Watch here for details of new products and services.
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Comparison
- Forums
- Visit our forums
- Jobs
- Visit our job site
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire New!
- Contact us
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
News of the day
Application filed for a transdermal absorption-type continuous-action drug to treat cancer pain
June 26, 2008 -- Hisamitsu Pharmaceutical Co., Inc. (Hisamitsu; TSE:4530) announced that as of today Hisamitsu has filed an application for new drug approval with Ministry of Health, Labour and Welfare for use of a transdermal absorption-type continuous-action drug for the treatment of cancer pain (development code: HFT-290). moreAlkermes Initiates Phase 3 Clinical Study of VIVITROL(R) for the Treatment of Opioid Dependence
CAMBRIDGE, Mass.--June 26, 2008--Alkermes, Inc. (NASDAQ: ALKS) today announced the initiation of a phase 3 clinical trial of VIVITROL(R) (naltrexone for extended-release injectable suspension) for the treatment of opioid dependence. The multi-center study is designed to assess the efficacy and safety of VIVITROL in approximately 200 patients diagnosed with opioid dependence. The clinical data from this study will form the basis of a supplemental New Drug Application (sNDA) to the U.S. Food and... moreNew Data Show Preemptive Treatment May Significantly Reduce Skin Toxicities in Patients Receiving Vectibix(R) (Panitumumab)
BARCELONA, Spain--June 26, 2008--Amgen (NASDAQ: AMGN) today announced updated results from the STEPP (Skin Toxicity Evaluation Protocol with Panitumumab) trial, the first prospective study to examine differences between preemptive and reactive skin treatment for skin toxicities in metastatic colorectal cancer (mCRC) patients receiving epidermal growth factor receptor (EGFr) therapy. The analysis found that preemptive treatment reduced the incidence rate of grade 2 and greater skin toxicities by... moreIndustry news search
Most Viewed News
- Nufarm acquires DuPont cotton portfolio
- Teva Announces Tentative Approval of Generic DiovanŽ Tablets
- AMRI to Receive Second Milestone Payment From Licensing Agreement with Bristol-Myers Squibb
- Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
- Finnish Red Cross Blood Service Licenses Ariadne Pathway Studio Enterprise
- RSS Feed...
Latest news by category
Development
- Optimer Reports Additional Data on Investigational Compound OPT-80 at Anaerobe 2008 Congress
- AspenBio Pharma Commences FDA Clinical Trial for AppyScore(TM) Appendicitis Blood Test
- St. Jude Medical Announces First Patient Implants in Clinical Study Evaluating Deep Brain Stimulation for Depression
- More news...
Company releases
- Because of its ability to generate higher total sales in the United States and Europe, Lucentis will earn Clinical Gold Standard Status by 2011 for the treatment of Diabetic Retinopathy
- China’s Renal Cell Carcinoma drug market will grow more than five-fold by 2012
- Renal Cell Carcinoma drug market will more than double over the next decade, rising from US$ 625 million in 2007 to nearly US$ 1.6 billion in 2017
- More news...
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us